We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Vaccine Manufacture and Supply – News and Features

News

Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions

Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
News

FRAUNHOFER CENTERS IN NEWARK, DE, AND AT BOSTON UNIVERSITY DEVELOP PLANT-BASED VACCINE FACTORY BASED ON PROPRIETARY EXPRESSION TECHNOLOGY OF IBIO, INC.

A first-of-a-kind, plant-based vaccine factory, takes advantage of plant viral vector technology developed by Fraunhofer CMB for the biopharmaceutical company iBio.
News

CDC Expands Existing Vaccine Distribution Partnership with McKesson to Include H1N1 Flu Vaccine

Expansion includes the centralized distribution of the H1N1 flu vaccine to as many as 90,000 sites across the U.S.
News

Baxter Advances to Full-Scale Production of A/H1N1 Vaccine

Baxter has started full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology.
News

Baxter Receives EMEA Positive Opinion for CELVAPAN, the First Cell Culture-Based Pandemic Flu Vaccine

Clinical data from a Phase III and subsequent booster study demonstrate safety, immune response and cross-protective memory.
News

Novavax announces favourable results from PhaseI/IIa Pandemic Influenza Vaccine Program

Novavax, Inc. announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain.
News

Ebola Virus Disarmed by Excising a Single Gene

Researchers have figured out a way to genetically disarm the virus and making the agent safe to study under conditions far less stringent than those currently imposed.
News

Cambridge Biostability Invests £1M in Commercial Spray Drier

The £1million facility will produce clinical trial material manufactured to the approved quality.
Advertisement